Previously, different studies reported that a cisplatin-gemcitabine combination, paclitaxel-based regimen or TKI-based therapy led to a downregulation of the PD-L1 expression of tumour cells (Sheng et al. 2016; Rojkó et al. 2018). This evidence concerns the gene CD274 and neoplasm.